FDA Quality Metrics Could Lead Market to Pay for Quality, Prevent Shortages, Woodcock Says
This article was originally published in The Gold Sheet
Executive Summary
FDA aims to establish quality metrics that GPOs could use to choose the most robust, highest quality drug manufacturers, CDER Director Janet Woodcock says. Move could strengthen position of quality units as firms shift to compete on quality instead of price.
You may also be interested in...
Public-Private Consortium To Strengthen Essential Medicines Supply Under White House Initiative
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.
US FDA Launches Quality Maturity Pilots That Reward High-Performing OTC, Rx Manufacturers
One pilot target domestic manufacturers of finished drugs and another foreign manufacturers of APIs. As an incentive to participate, companies assigned high scores will be accorded regulatory flexibility. Also, participants that disclose facility ratings could “benefit from a competitive advantage.”
US FDA Launches Quality Maturity Pilot Program That Rewards High-Performing Manufacturers
High ratings on factors like quality culture could yield post-approval change flexibility for participating drug product and API manufacturing facilities.